Breaking: Juno Therapeutics (NASDAQ:JUNO) “Outperform” Rating Reiterated by Analysts at Leerink Swann Today; The Target Price per Share is Set to $56

November 15, 2017 - By Dolores Ford

 Breaking: Juno Therapeutics (NASDAQ:JUNO)

Investors sentiment increased to 1.33 in Q2 2017. Its up 0.22, from 1.11 in 2017Q1. It is positive, as 21 investors sold Juno Therapeutics Inc shares while 40 reduced holdings. 38 funds opened positions while 43 raised stakes. 53.50 million shares or 13.76% more from 47.03 million shares in 2017Q1 were reported.

Credit Suisse Ag invested in 210,051 shares. Edge Wealth Mngmt Ltd Llc stated it has 100 shares. Qs Investors Limited Liability owns 4,500 shares or 0% of their US portfolio. Deutsche Natl Bank Ag holds 0% or 232,460 shares. Legal & General Gru Public Lc owns 22,779 shares or 0% of their US portfolio. 1,000 were accumulated by Captrust Financial Advsrs. Macquarie Limited stated it has 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Dekabank Deutsche Girozentrale has invested 0.01% in Juno Therapeutics Inc (NASDAQ:JUNO). Voya Investment Mngmt Ltd Liability Co owns 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 17,799 shares. Marshall Wace Llp owns 35,687 shares for 0.05% of their portfolio. Baker Bros Advsr L P owns 50,000 shares for 0.01% of their portfolio. Hudson Bay Management L P invested in 100,000 shares or 0.06% of the stock. Aperio invested in 28,360 shares or 0.01% of the stock. Mitsubishi Ufj And Banking has 901,750 shares. Bessemer Gp Incorporated has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO).

Juno Therapeutics (NASDAQ:JUNO) Rating Reaffirmed

Juno Therapeutics (NASDAQ:JUNO) just had their share rating of a ‘”Outperform”‘ issued by research analysts at Leerink Swann, who now has a $56 PT on the $6.14 billion market cap company or a 4.11 % upside potential. This key information was revealed in a research report on 2 November.

Investors sentiment increased to 1.33 in Q2 2017. Its up 0.22, from 1.11 in 2017Q1. It is positive, as 21 investors sold Juno Therapeutics Inc shares while 40 reduced holdings. 38 funds opened positions while 43 raised stakes. 53.50 million shares or 13.76% more from 47.03 million shares in 2017Q1 were reported.

Credit Suisse Ag invested in 210,051 shares. Edge Wealth Mngmt Ltd Llc stated it has 100 shares. Qs Investors Limited Liability owns 4,500 shares or 0% of their US portfolio. Deutsche Natl Bank Ag holds 0% or 232,460 shares. Legal & General Gru Public Lc owns 22,779 shares or 0% of their US portfolio. 1,000 were accumulated by Captrust Financial Advsrs. Macquarie Limited stated it has 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Dekabank Deutsche Girozentrale has invested 0.01% in Juno Therapeutics Inc (NASDAQ:JUNO). Voya Investment Mngmt Ltd Liability Co owns 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 17,799 shares. Marshall Wace Llp owns 35,687 shares for 0.05% of their portfolio. Baker Bros Advsr L P owns 50,000 shares for 0.01% of their portfolio. Hudson Bay Management L P invested in 100,000 shares or 0.06% of the stock. Aperio invested in 28,360 shares or 0.01% of the stock. Mitsubishi Ufj And Banking has 901,750 shares. Bessemer Gp Incorporated has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO).

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Among 16 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Juno Therapeutics Inc has $73 highest and $24.0 lowest target. $50.27’s average target is -6.54% below currents $53.79 stock price. Juno Therapeutics Inc had 43 analyst reports since July 22, 2015 according to SRatingsIntel. Raymond James upgraded the shares of JUNO in report on Tuesday, August 29 to “Buy” rating. The stock has “Outperform” rating by Leerink Swann on Thursday, November 2. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Outperform” rating given on Friday, July 8 by FBR Capital. On Tuesday, December 6 the stock rating was downgraded by Raymond James to “Mkt Perform”. The rating was downgraded by JP Morgan on Friday, July 8 to “Neutral”. The firm has “Buy” rating given on Thursday, November 2 by SunTrust. The firm earned “Outperform” rating on Wednesday, July 22 by Northland Capital. The rating was maintained by Raymond James on Friday, November 3 with “Buy”. The firm earned “Equal-Weight” rating on Wednesday, July 6 by Barclays Capital. Standpoint Research initiated the shares of JUNO in report on Monday, August 24 with “Buy” rating.

About 31,933 shares traded. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since November 15, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.

Analysts expect Juno Therapeutics Inc (NASDAQ:JUNO) to report $-1.02 EPS on March, 7.They anticipate $0.36 EPS change or 54.55 % from last quarter’s $-0.66 EPS. After having $-1.12 EPS previously, Juno Therapeutics Inc’s analysts see -8.93 % EPS growth.

Juno Therapeutics, Inc. is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The company has market cap of $6.14 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.

More notable recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Businesswire.com which released: “Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday …” on October 25, 2017, also Nasdaq.com with their article: “Commit To Purchase Juno Therapeutics At $32.50, Earn 11.1% Using Options” published on October 23, 2017, Businesswire.com published: “Robbins Arroyo LLP: Juno Therapeutics, Inc. (JUNO) Misled Shareholders …” on November 14, 2017. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) were released by: Businesswire.com and their article: “Juno Therapeutics to Present at November 2017 Investor Conferences” published on November 01, 2017 as well as Fool.com‘s news article titled: “Why Juno Therapeutics Shares Are Going Up 21.2% Today” with publication date: November 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.